- Home
- EVF vs IMMX Comparison
EVF vs IMMX Comparison
Compare EVF & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVF
- IMMX
- Stock Information
- Founded
- EVF 1998
- IMMX 2014
- Country
- EVF United States
- IMMX United States
- Employees
- EVF N/A
- IMMX N/A
- Industry
- EVF Investment Managers
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- EVF Finance
- IMMX Health Care
- Exchange
- EVF Nasdaq
- IMMX Nasdaq
- Market Cap
- EVF 101.0M
- IMMX 82.6M
- IPO Year
- EVF N/A
- IMMX 2021
- Fundamental
- Price
- EVF $5.42
- IMMX $3.28
- Analyst Decision
- EVF
- IMMX Strong Buy
- Analyst Count
- EVF 0
- IMMX 1
- Target Price
- EVF N/A
- IMMX $8.00
- AVG Volume (30 Days)
- EVF 93.3K
- IMMX 769.8K
- Earning Date
- EVF 01-01-0001
- IMMX 11-07-2025
- Dividend Yield
- EVF 10.68%
- IMMX N/A
- EPS Growth
- EVF N/A
- IMMX N/A
- EPS
- EVF 0.94
- IMMX N/A
- Revenue
- EVF N/A
- IMMX N/A
- Revenue This Year
- EVF N/A
- IMMX N/A
- Revenue Next Year
- EVF N/A
- IMMX N/A
- P/E Ratio
- EVF $6.74
- IMMX N/A
- Revenue Growth
- EVF N/A
- IMMX N/A
- 52 Week Low
- EVF $5.20
- IMMX $1.34
- 52 Week High
- EVF $6.84
- IMMX $4.05
- Technical
- Relative Strength Index (RSI)
- EVF 43.31
- IMMX 55.27
- Support Level
- EVF $5.38
- IMMX $2.85
- Resistance Level
- EVF $5.50
- IMMX $3.53
- Average True Range (ATR)
- EVF 0.04
- IMMX 0.38
- MACD
- EVF 0.00
- IMMX -0.07
- Stochastic Oscillator
- EVF 33.36
- IMMX 34.80
About EVF Eaton Vance Senior Income Trust
Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.